Company: RGNT
Filing Date: 2025-01-27
Form Type: DRS/A
Source: 0001213900-25-006676
Chunk: 152

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-01-27
Form: DRS/A
Chunk 152
---
 Dr. Alpert is a microbiologist and pediatrician
with a specialty in infectious diseases. She completed her undergraduate degree at Barnard College, Columbia University in New York City,
holds a master’s degree and Ph.D. in Biomedical Sciences from New York University and a medical degree from the University of Miami
(Florida). Dr. Alpert is a member of several non-profit and for-profit boards.

Family Relationships

There are no family relationships
between any members of our executive management and our directors.

Arrangements for Election of Directors and Members of Management

There
are no arrangements or understandings with major shareholders, customers, suppliers or others pursuant to which any of our executive management
or our directors were selected. See “Related Party Transactions” for additional information.

Compensation

The following table presents
in the aggregate all compensation we paid to all of our directors and senior management as a group for the year ended December 31, 2024.
The table does not include any amounts we paid to reimburse any of such persons for costs incurred in providing us with services during
this period.

<div align='center'>92</div>

All amounts reported in the
table below reflect our cost, in thousands of U.S. dollars. Amounts paid in NIS are translated into U.S. dollars at the rate of NIS 3.67
= U.S. $1.00, based on the average representative rate of exchange between the NIS and the U.S. dollar as reported by the Bank of Israel
during such period of time.

|                                                                                                     |     | Salary, bonuses and Related Benefits |         |     | Pension, Retirement and Other Similar Benefits |   |     | Share Based     
 Compensation(1) |   |
|:----------------------------------------------------------------------------------------------------|:----|:-------------------------------------|--------:|:----|:-----------------------------------------------|:--|:----|:----------------|:--|
| All directors and senior management as a group, consisting of five persons as of December 31, 2024. |     | $                                    | 218,000 |     | $                                              | - |     | $               | - |

For
so long as we qualify as a foreign private issuer, we will not be required to comply with the proxy rules applicable to U.S. domestic
companies regarding disclosure of the compensation of certain executive officers on an individual basis. Pursuant to the Companies Law,
we will be required, after we become a public company, to disclose the annual compensation of our five most